ASCEND BY NTHRYS
Research Abroad Products

Genetics Project Topics

Browse all focused areas across all project categories under this field.

Showing 841–852 of 2020 project topics
Stickler Syndrome COL2A1 and COL11 Genetics
Characterizing COL2A1, COL11A1, and COL11A2 variants causing Stickler syndrome for molecular diagnosis and ophthalmological surveillance planning.
Genetics of Connective Tissue and Joint Disorders Click to view more details →
Familial Hypermobility Genetics Research
Investigating genetic basis of hypermobile EDS and related joint hypermobility spectrum using family studies and genomic approaches.
Genetics of Connective Tissue and Joint Disorders Click to view more details →
Osteoarthritis Genetic Risk Variant Discovery
Identifying common genetic variants contributing to osteoarthritis susceptibility through GWAS in large joint disease cohorts.
Genetics of Connective Tissue and Joint Disorders Click to view more details →
Rheumatoid Arthritis HLA and Non-HLA Genetics
Characterizing HLA-DRB1 shared epitope alleles and non-HLA GWAS variants contributing to RA susceptibility and therapeutic response.
Genetics of Connective Tissue and Joint Disorders Click to view more details →
Ehlers-Danlos Syndrome Mutation Screening SaaS Platform
A cloud-based diagnostic platform that sequences and analyzes COL1A1, COL1A2, COL3A1, and other EDS-associated genes to enable rapid clinical confirmation and subtype classification. Generates recurring licensing revenue from clinical laboratories and genetic testing companies while reducing turnaround time from weeks to days.
Genetics of Connective Tissue and Joint Disorders Click to view more details →
Marfan Syndrome FBN1 Variant Interpretation Commercial Database
A proprietary curated database and API service that aggregates FBN1 mutations with clinical phenotype correlations and cardiovascular risk predictions for genetic counselors and clinicians. Monetizes through subscription access for hospitals, diagnostic laboratories, and telemedicine providers seeking evidence-based risk stratification tools.
Genetics of Connective Tissue and Joint Disorders Click to view more details →
Osteogenesis Imperfecta Severity Prediction Machine Learning Tool
An AI-powered software tool that predicts OI disease severity and fracture risk using COL1A1/COL1A2 genotypes combined with clinical and imaging biomarkers. Delivers value through early intervention planning for orthopedic device manufacturers and pharmaceutical companies developing OI therapeutics.
Genetics of Connective Tissue and Joint Disorders Click to view more details →
Systemic Sclerosis Susceptibility Polygenic Risk Score Commercial Service
A clinical genomics service that calculates polygenic risk scores integrating NOTCH4, FAP, IRF5, and emerging SSc-associated variants for patient stratification and early diagnosis. Creates revenue through B2B contracts with rheumatology practices, insurance companies, and pharmaceutical sponsors conducting precision medicine trials.
Genetics of Connective Tissue and Joint Disorders Click to view more details →
Lupus Genetic Risk Variant Panel Diagnostic Kit Development
A commercialized genetic testing kit targeting HLA-DRB1, STAT4, IRF5, and complement pathway variants to identify systemic lupus erythematosus susceptibility in at-risk populations. Generates B2C and B2B revenue through direct-to-consumer sales, physician ordering, and licensing to regional diagnostic laboratories.
Genetics of Connective Tissue and Joint Disorders Click to view more details →
Ankylosing Spondylitis HLA-B27 and Genetic Modifier Profiling Service
An integrated genomic profiling service combining HLA-B27 typing with non-HLA genetic modifiers and IL-23 pathway variants to enable treatment response prediction and drug selection optimization. Monetizes through partnerships with rheumatology centers, biologic drug manufacturers, and personalized medicine platforms targeting refractory AS patients.
Genetics of Connective Tissue and Joint Disorders Click to view more details →
Tumor Mutational Burden Assessment Pipeline
Developing TMB calculation methods from tumor sequencing panels for identifying patients likely to respond to immune checkpoint inhibitor therapy.
Precision Oncology Genetics Click to view more details →
Homologous Recombination Deficiency Scoring
Developing HRD scores integrating LOH, telomeric allelic imbalance, and LST for identifying BRCA-like tumors likely to respond to PARP inhibitors.
Precision Oncology Genetics Click to view more details →